Progress in application of medical absorbable haemostatic materials for haemostasis in orthopaedic surgery.
10.7507/1002-1892.202405068
- Author:
Gang WANG
1
;
Yi ZENG
1
Author Information
1. Department of Orthopaedics, Institute of Orthopaedics, West China Hospital, Sichuan University, Chengdu Sichuan, 610041, P. R. China.
- Publication Type:English Abstract
- Keywords:
Medical absorbable hemostatic material;
biocompatibility;
haemostatic mechanism;
orthopaedic surgery
- MeSH:
Humans;
Hemostatics;
Orthopedic Procedures/methods*;
Hemostasis, Surgical/methods*;
Biocompatible Materials;
Cellulose, Oxidized;
Chitosan;
Fibrin Tissue Adhesive;
Gelatin;
Blood Loss, Surgical/prevention & control*;
Hemostasis/drug effects*
- From:
Chinese Journal of Reparative and Reconstructive Surgery
2024;38(11):1421-1426
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:The application progress of medical absorbable haemostatic material (MAHM) in hemostasis during orthoapedic surgery was reviewed, in order to provide reference for clinical hemostasis program.
METHODS:The domestic and foreign literature on the application of MAHM for hemostasis in orthopedic surgery was extensively reviewed and summarized.
RESULTS:According to biocompatibility, MAHM can be divided into oxidized cellulose/oxidized regenerated cellulose materials, chitosan and its derivatives materials, starch materials, collagen and gelatin materials, and fibrin glue materials, etc., which can effectively reduce blood loss when used in orthopedic surgery for hemostasis. Each hemostatic material has different coagulation mechanism and suitable population. Oxidized cellulose/oxidized regenerated cellulose, chitosan and its derivatives, starch hemostatic material mainly stops bleeding by stimulating blood vessel contraction and gathering blood cells, which is suitable for people with abnormal coagulation function. Collagen, gelatin and fibrin glue hemostatic materials mainly affect the physiological coagulation mechanism of the human body to stop bleeding, suitable for people with normal coagulation function.
CONCLUSION:Reasonable selection of MAHM can effectively reduce perioperative blood loss and reduce the risk of postoperative complications, but at present, single hemostatic material can not meet clinical needs, and a new composite hemostatic material with higher hemostatic efficiency needs to be developed.
